Document Detail


Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty.
MedLine Citation:
PMID:  12061389     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Tissue factor pathway inhibitor (TFPI) has anti-proliferative and anti-migratory effects on cultured smooth muscle cells (SMC) in addition to its anti-thrombotic activity. Here, we assess how long locally delivered recombinant TFPI (rTFPI) remains detectable at the delivery sites and clarify the main mechanism by which rTFPI blocks neointimal growth in vivo. METHODS: The iliac arteries of 85 Japanese white rabbits were injured using a Cutting Balloon. First, to establish the efficacy of local delivery of rTFPI, 5 groups of 3 rabbits each were examined immediately or 1, 2, 4 or 7 days after delivery. They were treated locally with a total amount of 200 microg of rTFPI given at 40 microg per pulse per minute by means of a Pulse Spray catheter. Thereafter, 34 rabbits which had received 200 microg of rTFPI after cutting angioplasty were compared to the same number of controls regarding thrombosis, inhibition of neointimal proliferation and inflammation. RESULTS: A total of 2.6+/-1.6 ng rTFPI persisted on the injured vessel 4 days after delivery. rTFPI was still present on 48 % of the cut sites 7 days after delivery, despite its short half-life in plasma. Thrombosis in the rTFPI-treated group was significantly reduced compared to the controls. The number of macrophages present within the media and intima was significantly decreased at day 7 after delivery of rTFPI. Furthermore, the number of Ki-67-positive cells 14 days after rTFPI delivery was significantly lower than in controls although there were no significant differences between them after 2 days. CONCLUSIONS: Local delivery of rTFPI decreased the degree of neointimal formation 4 weeks after TFPI delivery because of anti-inflammatory and anti-proliferative effects in addition to, or rather than, via anti-thrombosis.
Authors:
Yoichi Nakamura; Kazufumi Nakamura; Keiko Ohta; Hiromi Matsubara; Chikao Yutani; Tsutomu Hamuro; Hisao Kato; Tohru Ohe
Related Documents :
6652049 - Portsmouth operative delivery trial: a comparison vacuum extraction and forceps delivery.
20383839 - Predictors of severe neonatal compromise following caesarean section for clinically dia...
724169 - Shoulder dystocia. a complication of fetal macrosomia and prolonged second stage of lab...
3692879 - Perinatal factors in the aetiology of hypopituitarism.
40589 - Normal values for fetal scalp tissue ph during labour.
17685209 - Caesarian section rates and perinatal outcome at the aga khan university hospital, nair...
17297249 - Eosinophil cationic protein and chemokines in nasopharyngeal secretions of infants with...
9419869 - Statistical classification of seafood quality.
1105059 - Experimental congenital malformations.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Basic research in cardiology     Volume:  97     ISSN:  0300-8428     ISO Abbreviation:  Basic Res. Cardiol.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-06-13     Completed Date:  2002-12-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0360342     Medline TA:  Basic Res Cardiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  198-205     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry, Japan. ynakamur@mti.biglobe.ne.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Balloon*
Animals
Anti-Inflammatory Agents / administration & dosage,  therapeutic use*
Catheterization
Cell Division / drug effects
Cricetinae
Cricetulus
Equipment Design
Fibrinolytic Agents / therapeutic use*
Humans
Iliac Artery / drug effects,  pathology
Macrophages / pathology
Rabbits
Recombinant Proteins / administration & dosage,  therapeutic use*
Thrombosis / prevention & control
Tissue Plasminogen Activator / administration & dosage,  therapeutic use*
Tunica Intima / drug effects,  pathology
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Fibrinolytic Agents; 0/Recombinant Proteins; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Embryogenesis of the rat heart: the expression of collagenases.
Next Document:  Progressive heart failure after myocardial infarction in mice.